Core Viewpoint - Bit Digital, Inc. has announced a registered direct offering of 22 million ordinary shares at a price of $3.06 per share, aiming to raise approximately $67.3 million in gross proceeds before fees and expenses [1][2]. Group 1: Offering Details - The offering is expected to close around July 15, 2025, pending customary closing conditions [1]. - The net proceeds from the offering will be utilized to purchase Ethereum [2]. - B. Riley Securities is acting as the exclusive Placement Agent for this offering [2]. Group 2: Regulatory Information - The securities are being offered under a shelf registration statement on Form S-3, which was filed with the SEC on April 30, 2025, and declared effective on June 20, 2025 [3]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus supplement will also be filed and made available on the SEC's website [3]. Group 3: Company Overview - Bit Digital is a publicly traded digital asset platform focused on Ethereum-native treasury and staking strategies, having begun to accumulate and stake ETH in 2022 [5]. - The company operates one of the largest institutional Ethereum staking infrastructures globally, offering advanced validator operations and institutional-grade custody [5]. - Bit Digital aims to provide secure, scalable, and compliant access to on-chain yield through strategic partnerships within the Ethereum ecosystem [5].

Core Viewpoint - SeaStar Medical Holding Corporation has announced a definitive agreement for the issuance and sale of 5,242,464 shares of common stock at a price of $0.763 per share, along with unregistered warrants to purchase an equal number of shares at an exercise price of $0.638, aiming to raise approximately $4 million for general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a registered direct offering priced at-the-market under Nasdaq rules and a concurrent private placement for unregistered warrants [1][2]. - The gross proceeds from the offering are expected to be around $4 million, with net proceeds intended for general corporate purposes, including working capital and capital expenditures [2]. Group 2: Regulatory and Compliance Information - The shares are being offered under a shelf registration statement previously filed with the SEC, which became effective on December 22, 2023 [3]. - The unregistered warrants are not registered under the Securities Act and cannot be sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first product, QUELIMMUNE, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients [6]. - The company’s Selective Cytopheretic Device therapy has received Breakthrough Device Designation for six therapeutic indications, indicating a potential for expedited approval processes [6]. - SeaStar is conducting a pivotal trial of its SCD therapy in adult patients with acute kidney injury, a condition affecting over 200,000 adults in the U.S. annually [6].

Core Viewpoint - Cyngn Inc. has announced a registered direct offering with a single institutional investor, raising approximately $17.2 million through the sale of shares and pre-funded warrants at a price of $7.50 per share [1][3]. Group 1: Offering Details - The offering includes the sale of 2,293,333 shares of Common Stock or Pre-Funded Warrants, with the public offering price set at $7.50 per share [2]. - Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised, with a minimal exercise price of $0.00001 [2]. - The transaction is expected to close around June 30, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Information - Aegis Capital Corp. is the exclusive placement agent for the offering, while Sichenzia Ross Ference Carmel LLP and Kaufman & Canoles, P.C. are acting as legal counsel for the company and the placement agent, respectively [4]. Group 4: Company Overview - Cyngn develops autonomous vehicle technology aimed at addressing challenges faced by industrial organizations, such as labor shortages and safety incidents [8]. - The company's DriveMod technology allows customers to integrate self-driving technology into their operations without significant upfront costs or infrastructure changes [9]. - DriveMod is currently available on specific models like Motrec MT-160 Tuggers and BYD Forklifts, with capabilities such as hauling up to 12,000 lbs and a payback period of less than 2 years [10].

Core Points - Houston American Energy Corp. has entered into a definitive agreement for the purchase and sale of 81,629 shares of common stock at a price of $14.80 per share in a registered direct offering [1] - The gross proceeds from this offering are expected to be approximately $1.2 million, with net proceeds of around $1 million intended for general corporate purposes [2] - The offering is being conducted under a shelf registration statement previously filed and declared effective by the SEC [3] - The company has appointed Univest Securities, LLC as the sole placement agent for the offering, entitled to an 8.0% fee on the proceeds [4]

Company Overview - Houston American Energy Corp. is an independent oil and gas company engaged in the acquisition, exploration, exploitation, development, and production of natural gas, crude oil, and condensate [7] - The company's principal properties are located primarily in the Texas Permian Basin, Colombia, and the onshore Louisiana Gulf Coast region [7] Offering Details - Houston American Energy Corp. has completed a registered direct offering, selling 223,762 shares of common stock at a purchase price of $10.60 per share, resulting in gross proceeds of approximately $2.37 million [2][3] - The net proceeds from the offering, estimated at approximately $2.1 million, are intended for general corporate purposes [3] Placement Agent - Univest Securities, LLC acted as the sole placement agent for the offering [3]

Core Viewpoint - Houston American Energy Corp. has entered into a definitive agreement for a registered direct offering of 223,762 shares at a price of $10.60 per share, expected to raise approximately $2.37 million in gross proceeds [1][2]. Group 1: Offering Details - The offering is expected to close on or about June 20, 2025, subject to customary closing conditions [2]. - The net proceeds from the offering, estimated at approximately $2.1 million, will be used for general corporate purposes [2]. - The offering is made under a shelf registration statement previously filed and declared effective by the SEC [3]. Group 2: Placement Agent Agreement - The Company has appointed Univest Securities, LLC as the sole placement agent for the offering, entitled to an 8.0% fee on the proceeds and reimbursement for expenses not exceeding $10,000 [4]. Group 3: Equity Purchase Agreement - The Company and the institutional investor had discussions about an equity purchase agreement but decided not to execute it at this time [5]. - If reconsidered, the agreement could allow the Company to sell up to $30 million of common stock over a 24-month term, with the purchase price expected to be approximately 96% of the lowest daily volume-weighted average price during the three trading days following a purchase notice [5].

Core Viewpoint - authID Inc. has announced a definitive agreement to sell approximately 373,060 shares of its common stock at a price of $5.60 per share, aiming to raise approximately $2.1 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The Registered Direct Offering is expected to close on or about May 7, 2025, pending customary closing conditions [2]. - Dominari Securities LLC and Madison Global Partners, LLC are acting as Co-Placement Agents for the offering [2]. - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on December 13, 2024 [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [2]. Group 3: Company Overview - authID Inc. specializes in biometric identity verification and authentication solutions, ensuring enterprises can accurately identify users behind devices [5]. - The company’s biometric identity platform offers rapid identity proofing in 700 milliseconds and authentication in 25 milliseconds, with a high accuracy rate and no storage of biometric data [5].

Core Viewpoint - Iterum Therapeutics plc has entered into a definitive agreement for a registered direct offering of 5,555,556 ordinary shares at a price of $0.90 per share, expected to close around April 30, 2025 [1][3] Group 1: Offering Details - The gross proceeds from the offering are anticipated to be approximately $5 million before deducting fees and expenses [3] - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The offering is conducted under a shelf registration statement filed with the SEC, effective since October 17, 2022 [4] Group 2: Use of Proceeds - The net proceeds will be used for working capital and general corporate purposes, including ongoing strategic processes and pre-commercialization activities [3] - Specific uses for the proceeds have not been identified, but they may fund expenses related to the commercialization of ORLYNVAH™, including manufacturing, sales, and marketing [3][6] Group 3: Company Overview - Iterum Therapeutics focuses on developing next-generation antibiotics to combat multi-drug resistant pathogens [6] - The company is advancing its first compound, sulopenem, which has shown potent activity against various resistant bacteria [6] - ORLYNVAH™ has received FDA approval for treating uncomplicated urinary tract infections in women with limited treatment options [6]

Core Viewpoint - Wang & Lee Group, Inc. has entered into a securities purchase agreement to sell 3,529,400 ordinary shares at a price of $3.40 per share, along with Series A and Series B warrants [1][2]. Group 1: Securities Offering Details - The total gross proceeds from the offering are estimated to be approximately $12,000,000 before deducting fees and expenses [2]. - The Series A warrants can be exercised at an exercise price of $3.40 per share and are valid for five years from issuance [1]. - Series B warrants will have an initial exercise price of $0.0001 per share and will be exercisable three trading days after issuance [1]. Group 2: Company Background - Wang & Lee Group, Inc. is a Hong Kong-based construction prime and subcontractor specializing in Electrical & Mechanical Systems installation [5]. - The company provides services for both public and private sectors, including design and contracting services across various trades in the construction industry [5].

Core Viewpoint - Acurx Pharmaceuticals has announced a definitive agreement for the purchase and sale of 2,745,000 shares of its common stock at a price of $0.40 per share, along with a concurrent private placement of unregistered short-term warrants to purchase up to 8,235,000 shares of common stock [1][2] Group 1: Offering Details - The total gross proceeds from the offering are expected to be approximately $1.1 million before deducting fees and expenses [2] - The warrants will have an exercise price of $0.40 per share and will expire twenty-four months after stockholder approval [1] - The closing of the offering is anticipated to occur around March 10, 2025, subject to customary closing conditions [1] Group 2: Company Background - Acurx Pharmaceuticals is focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [6] - The company's lead product candidate, ibezapolstat, is ready for Phase 3 trials for the treatment of C. difficile infection, with plans for international clinical trials this year [6] - The R&D pipeline includes antibiotic candidates targeting Gram-positive bacteria, including MRSA, VRE, and anthrax [6]